Morgan Stanley stock is in a buy zone of a base. A biometric identity name hit a new high after rebounding following a sell signal.

Morgan Stanley is upgraded to a 'Buy', driven by robust top-line growth, margin recovery, and strong competitive positioning. Morgan Stanley demonstrates proven revenue growth, positive client inflows, and benefits from M&A and resilient equity markets, supporting its diversified business model. Despite signs of overvaluation and modest 7% upside forecasts, its A-level credit ratings, strong liquidity, and low payout ratio reinforce its quality profile.

In the most recent trading session, Morgan Stanley (MS) closed at $200.51, indicating a +1.39% shift from the previous trading day.

NEW YORK--(BUSINESS WIRE)--Morgan Stanley (NYSE: MS) today announced the winners of its 17th annual Strategy Challenge, the Firm's flagship pro bono program which brings together rising talent to help nonprofits solve strategic, mission-critical challenges. The winning teams supported Hour Children in the U.S. and Mental Health Innovations in the UK. Over the past 10 weeks, Morgan Stanley employees provided in-depth, pro bono consulting services to 14 nonprofits on topics such as expanding prog.

When tech stocks are flying high, it can be easy to forget about the steady, dividend-paying stocks that often stabilize a portfolio.

WSJ reports that Goldman Sachs will lead the SpaceX IPO next month. Fees on the IPO could exceed $1 billion and will be shared among 21 underwriting banks.

Morgan Stanley has asked its Hong Kong-based bankers ​to carry new mobile devices issued ‌exclusively for business travel to mainland China, as international firms with a cross-border workforce tighten ​data security.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Passkey Therapeutics, the architect of the Locksmith® platform for systematically identifying new therapeutic opportunities from synergistic drug combinations, today announced the appointment of Mandeep Kaur, MD, MS, as Chief Medical Officer. Dr. Kaur will lead Passkey's clinical and medical strategy as it advances a series of Locksmith-identified drug combinations into clinical studies across multiple therapeutic areas. Dr. Kaur most recently served as Senior.

The financial services giant saw a 48% increase in investment banking fees in Q1.

[url="]Morgan Stanley at Work[/url] today issued new data from its sixth annual State of the Workplace Financial Benefits Study. The research reveals workpla